Physician profile
Baowei Tang
NPI 1427084607
$10,402.94
in general payments reported to CMS, 2019-2025
32 companies · $2,982 in 2025
The $2,982 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2021: $281 · 2022: $1,143 · 2023: $2,903 · 2024: $2,943 · 2025: $2,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,345 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,345.41 |
| Education | $483.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,086.04 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,865.83 | 2021-2025 | Tavneos, Krystexxa, Otezla |
| Abbvie INC. | $1,449.90 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $957.98 | 2022-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $640.60 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $629.16 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $371.94 | 2022-2025 | |
| Pfizer INC. | $313.18 | 2022-2025 | |
| Organon LLC | $231.52 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.35 | 2023-2025 | Ofev, Cyltezo |
| Sobi, INC | $199.46 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $188.20 | 2022-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $147.19 | 2024-2025 | Orencia |
| Sandoz INC. | $143.97 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $124.58 | 2023-2024 | Idacio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $116.02 | 2024 | Voquezna |
| Lilly USA, LLC | $113.90 | 2024-2025 | Taltz |
| Actelion Pharmaceuticals US, INC. | $89.58 | 2022-2025 | Opsynvi, Uptravi |
| Aurinia Pharma U.S., INC. | $76.82 | 2024-2025 | Lupkynis |
| Exact Sciences Corporation | $76.20 | 2023 | |
| Genzyme Corporation | $64.45 | 2023-2024 | |
| Radius Health, INC. | $60.45 | 2022-2023 | Tymlos |
| Genentech USA, INC. | $44.97 | 2025 | Actemra |
| Janssen Scientific Affairs, LLC | $43.81 | 2021 | |
| Alexion Pharmaceuticals, INC. | $41.31 | 2023 | Strensiq |
| Kiniksa Pharmaceuticals International, Plc | $19.62 | 2024 | Arcalyst |
| Ani Pharmaceuticals, INC. | $19.23 | 2025 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $18.09 | 2025 | Teriparatide |
| Horizon Therapeutics Plc | $16.77 | 2023 | Krystexxa |
| Ferring Pharmaceuticals INC. | $14.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Kiniksa Pharmaceuticals, LTD. | $12.89 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baowei Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.